Related coverage linked through entity extraction aliases.
Aug 15, 2026
Biotech reagents market projected to hit $148.21B by 2030; life science reagents to reach $114.4B by 2033. Growth driven by precision diagnostics, genomics, and personalized medicine.
Aug 10, 2026
Thermo Fisher posted 10% revenue growth in Q2 and raised guidance; Danaher's Q1 revenue missed but EPS beat. Danaher cited bioprocessing and life sciences strength and expects growth to accelerate.
Aug 09, 2026
Revvity beat Q2 expectations, raised its full-year outlook, and launched new drug discovery platforms at SLAS2026. Revenue totaled $711 million with 3% organic growth.
May 25, 2026
New market reports project strong growth in pharmaceutical manufacturing: fill-finish is set to reach $21.04 billion by 2030, ampoule filling/sealing machines to grow at a 5.8% CAGR through 2035, and medical membranes to hit $6.6 billion by 2030.
May 08, 2026
Market reports project growth in omics-based clinical trials, Asia digital PCR consumables, and multi-omic fluidic samplers. The clinical trials market is set to reach $47.78B by 2030; fluidic samplers grow to $2.76B by 2036.
Mar 11, 2026
Life sciences attorneys will host a March 3 webinar on FDA draft guidances for cell and gene therapies. A March 31 webinar will examine 2026 drug development data from a survey of 150 industry leaders.
Jul 25, 2026
Flow chemistry, laboratory mixer, and industrial extruder markets are projected to grow significantly through 2035, driven by pharmaceutical continuous manufacturing, high R&D funding, and sustainability trends. Flow chemistry is expected to reach $12 billion, while laboratory mixers could hit $29.6 billion. Key players include Merck KGaA, BASF, and Lonza.
Jun 11, 2026
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
May 20, 2026
Research and Markets added two cell and gene therapy publications, including a tools and reagents market report forecasting growth from $12 billion in 2025 to $19.8 billion by 2030. The reports track approvals, financing, deals, and manufacturing developments.
Apr 22, 2026
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
Apr 12, 2026
Thermo Fisher Scientific entered a collaboration with Singapore's PRECISE to support the PRECISE SG100K biobank initiative. The company will supply proteomics capabilities for precision medicine research and biomarker discovery in Asia Pacific.
Mar 27, 2026
Origin Genomics launches to pursue germline gene editing research despite US prohibitions, while Thermo Fisher completes its $8.88 billion acquisition of Clario Holdings. Lucid Diagnostics reports Q4 revenue growth, and multiple partnerships form across the diagnostics and synthetic biology sectors.
Mar 05, 2026
The large molecule drug substance CDMO market is expected to grow at approximately 9% CAGR through 2031, driven by rising demand for biologics and biosimilars, streamlined regulatory approval pathways, and increasing FDA and EMA approvals for biologic therapies.
Mar 02, 2026
The global drug discovery services market is valued at $22.04 billion in 2025 and is forecast to reach $75.13 billion by 2034, growing at a 14.6% CAGR from 2026-2034, driven by rising industry demand and technological advancements.
Mar 02, 2026
AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
Feb 25, 2026
Industry leaders highlight advances in AI-enabled trial monitoring, real-world data interoperability, and protocol-driven eSource systems, while emphasizing the need for community engagement in diversity efforts and addressing operational risks in rare disease trials.
Feb 20, 2026
The clinical trials industry is expected to grow from $61.93 billion in 2025 to $99.25 billion by 2033 at a 6.07% CAGR, driven by demand for innovative therapies and chronic disease prevalence. Clinical trials management systems are projected to reach $9.0 billion by 2035.
Feb 25, 2026
The global precision medicine market reached $98.87 billion in 2024 and is projected to grow at 14.8% CAGR through 2033, driven by genomic sequencing advances, chronic disease prevalence, and AI-driven diagnostics adoption.
Feb 24, 2026
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.
Feb 18, 2026
The Preeclampsia Foundation released a new educational resource to help OB-GYNs navigate predictive and diagnostic biomarker testing for hypertensive disorders of pregnancy, covering FDA-cleared tests from Thermo Fisher Scientific and Roche Diagnostics.
